Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 1, 1999, Pages 77-84

  Entenza, J M ^a   Vouillamoz, J ^a   Glauser, M P ^a   Moreillon, P ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALATROFLOXACIN; CEFTRIAXONE; CIPROFLOXACIN; TROVAFLOXACIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL ENDOCARDITIS; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; INTRAVENOUS DRUG ADMINISTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOCOCCUS MITIS; STREPTOCOCCUS SANGUINIS;

EID: 0032963015     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.1.77     Document Type: Article

References (33)

1. Barry, A. L., S. D. Brown, and P. C. Fuchs. 1996. In vitro-selection of quinolone-resistant staphylococcal mutants by single exposure to ciprofloxacin or trovafloxacin (CP-99,219). J. Antimicrob. Chemother. 38:324-327.
2. Blatter, M., J. Entenza, P. Moreillon, and M. P. Glauser. 1993. Parenteral sparfloxacin compared to vancomycin in the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus, abstr. 150, p. 147. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Blouin, R. A., L. A. Bauer, D. D. Miller, K. E. Record, and W. O. Griffen. 1982. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob. Agents Chemother. 21:575-580.
4. Blum, M. D., D. J. Graham, and C. A. McCloskey. 1993 Temafloxacin syndrome: review of 95 cases. Clin. Infect. Dis. 18:946-950.
5. Borner, K., G. Höffken, H. Lode, P. Koeppe, C. Prinzing, P. Glatzel, R. Wiley, P. Olschewski, B. Sievers, and D. Reinitz. 1986. Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur. J. Clin. Microbiol. 5:179-186.
6. Bouvet, A., A. C. Cremieux, A. Contrepois, J. M. Vallois, C. Lamesch, and C. Carbon. 1985. Comparison of penicillin and vancomycin, individually and in combination with gentamicin and amikacin, in the treatment of experimental endocarditis induced by nutritionally variant streptococci. Antimicrob. Agents Chemother. 28:607-611.
7. Cars, O., and S. Ögren. 1981. A microtechnique for the determination of antibiotics in muscle. J. Antimicrob. Chemother. 8:39-48.
8. Child, J., J. Andrews, F. Boswell, N. Brenwald, and R. Wise. 1995. The in-vitro activity of CP-99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J. Antimicrob. Chemother. 35:869-876.
9. Craig, W. A., and B. Suh. 1991. Protein binding and the antimicrobial effects: methods for the determination of protein binding, p. 367-402. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. The Williams & Wilkins Co., Baltimore, Md.
10. Crémieux, A. C., A. Saleh-Mghir, J. M. Vallois, B. Mazière, M. Ottaviani, J. J. Pocidalo, and C. Carbon. 1991. Pattern of diffusion of three quinolones throughout infected cardiac vegetations studied by autoradiography, abstr. 357, p. 158. In Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
11. Domagala, J. M. 1994. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother. 33:685-706.
12. Dürack, D. T., P. B. Beeson, and R. G. Petersdorf. 1973. Experimental endocarditis. III. Production and progress of the disease in rabbits. Br. J. Exp. Pathol. 54:142-150.
13. Entenza, J. M., M. Blatter, M. P. Glauser, and P. Moreillon. 1994. Parenteral sparfloxacin compared with ceftriaxone in treatment of experimental endocarditis due to penicillin-susceptible and -resistant streptococci. Antimicrob. Agents Chemother. 38:2683-2688.
14. Entenza, J. M., U. Fluckiger, M. P. Glauser, and P. Moreillon. 1994. Antibiotic treatment of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis. J. Infect. Dis. 170:100-109.
15. Entenza, J. M., J. Vouillamoz, M. P. Glauser, and P. Moreillon. 1997. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 41:1662-1667.
16. Flückiger, U., P. Francioli, J. Blaser, M. P. Glauser, and P. Moreillon. 1994. Role of amoxicillin serum levels for successful prophylaxis of experimental endocarditis due to tolerant streptococci. J. Infect. Dis. 169:1397-1400.
17. Girard, A. E., D. Girard, T. D. Gootz, J. A. Faiella, and C. R. Cimochowski. 1995. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens. Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob. Agents Chemother. 39:2210-2216.
18. Gootz, T. D., R. Zaniewski, S. Haskell, B. Schmieder, J. Tankovic, D. Girard, P. Courvalin, and R. J. Polzer. 1996. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob. Agents Chemother. 40:2691-2697.
19. Heraief, E., M. P. Glauser, and L. Freedman. 1982. Natural history of aortic valve endocarditis in rats. Infect. Immun. 37:127-131.
20. Jones, R. N. 1994. Preliminary interpretative criteria for in vitro susceptibility testing of CP-99219 by dilution and disk diffusion methods. Diagn. Microbiol. Infect. Dis. 20:167-170.
21. Kaatz, G. W., S. L. Barriere, D. R. Schaberg, and R. Feketv. 1987. The emergence of resistance to ciprofloxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis. J. Antimicrob. Chemother. 20:753-758.
22. Kaatz, G. W., S. M. Seo, J. R. Aeschlimann, H. H. Houlihan, R. C. Mercier, and M. J. Rybak. 1998. Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 42: 254-256.
23. Naora, K., Y. Katagiri, N. Ichikawa, M. Hayashibara, and K. Iwamoto. 1990. A possible reduction of the renal clearance of ciprofloxacin by fenbufen in rats. J. Pharm. Pharmacol. 42:704-707.
24. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A3. National Committee for Clinical Laboratory Standards,. Wayne, Pa.
25. Norrby, S. R. 1989. Treatment of urinary tract infections with fluoroquinolone antibacterial agents, p. 107-123. In J. S. Wolfson and D. C. Hooper (ed.), Quinolone antimicrobial agents. American Society for Microbiology, Washington, D.C.
26. Patel, I. H., S. Chen, M. Parsonnet, M. R. Hackman, M. A. Brooks, J. Konikoff, and S. A. Kaplan. 1981. Pharmacokinetics of ceftriaxone in humans. Antimicrob. Agents Chemother. 20:634-641.
27. Piddock, L. J. 1994. New quinolones and gram-positive bacteria. Antimicrob. Agents Chemother. 38:163-169.
28. Piper, K. E., M. S. Rouse, R. Patel, W. R. Wilson, and J. M. Steckelberg. 1997. Trovafloxacin treatment of viridans streptococcal experimental endocarditis, abstr. B-20, p. 30. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C
29. Rouse, M. S., K. E. Piper, R. Patel, W. R. Wilson, and J. M. Steckelberg. 1997. In vitro and in vivo activity of trovafloxacin against methicillin-susceptible Staphylococcus aureus experimental endocarditis, abstr. B-26, p. 31. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
30. Stein, G. E. 1996. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin. Infect. Dis. 23(Suppl. 1):S19-S24.
31. Stoeckel, K., J. McNamara, R. Brandt, H. Plozza-Nottebrock, and W. H. Ziegler. 1981. The effects of concentration-dependent plasma protein binding on the pharmacokinetics of ceftriaxone (Ro 13-9904), a new parenteral cephalosporin. Clin. Pharmacol. Ther. 29:650-657.
32. Teng, R., D. Girard, T. D. Gootz, G. Foulds, and T. E. Liston. 1995. Pharmacokinetics of trovafloxacin (CP-29,219), a new quinolone, in rats, dogs, and monkeys. Antimicrob. Agents Chemother. 40:561-566.
33. Wise, R., D. Mortiboy, J. Child, and J. M. Andrews. 1996. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrob. Agents Chemother. 40:47-49.